quotable quotes - October 2010
bariatric surgery as a type 2 diabetes treatment?
"I actually know very little about diabetes, but I send it into remission weekly."
- Erik Dutson, MD (University of California, Los Angeles, Los Angeles, CA), a bariatric surgeon, drawing on his experience to note the power of bariatric surgery to treat not only obesity, but type 2 diabetes as well at the 28th annual meeting of The Obesity Society (TOS) in San Diego.
on type 1 diabetes – the future looks very bright indeed
"We’re going to conquer type 1 diabetes."
- Jay Skyler, MD (University of Miami Miller School of Medicine, Miami, FL) commenting confidently after reviewing the promising developments in immunotherapies and recent progress toward creating an artificial pancreas at the 46th annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.
hmm... maybe a multi-pronged attack will help us conquer diabetes
"Medicine might be winning the battle of glucose control, but it is losing the war against diabetes."
- Ulf Smith, MD (Gothenberg University, Gothenberg, Sweden) arguing for the need of new diabetes medications that target other aspects of diabetes, including cardiovascular risk and beta cell death, besides elevated glucose levels in his Presidential Address at the 46th annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.
recess is more than just fun and games
"At the very minimum, I would recommend 15 minutes of supervised, unstructured recess per day, in addition to 45 minutes of Physical Education, so a total of one hour. I don’t think it will wreck their math or science scores. On the contrary, they would study better and want to learn more because they are provided with a release from the mental challenges of academics."
- Melinda Sothern, PhD (Louisiana State University, New Orleans, LA) responding to a question regarding how much physical activity children in 1st or 2nd grade should have in order to fight childhood obesity at the 28th annual meeting of The Obesity Society (TOS) in San Diego.
reactions to the FDA’s decision on bydureon
"While this is difficult, especially for the millions of individuals with type 2 diabetes that don’t achieve adequate glycemic control with currently approved therapies, we remain confident that Bydureon is a transformational potential treatment option for patients, and we will work diligently to bring it to the market."
Daniel Bradbury (President and CEO of Amylin Pharmaceuticals) commenting on the decision by the FDA to delay the approval of Bydureon, the once-weekly GLP-1 agonist, once again last week.
